Prescott et al. [[37]]
|
Barriers to participation in clinical trials: patient and clinician barriers
|
Barriers
|
Classification
|
Factor derived
|
Patient barriers
|
Additional demands of the randomized controlled trials (RCT) on the patient
|
Patient level factors
|
Additional trial investigations
|
Additional procedures, additional appointments, time pressures, venepuncture, inpatient hospital stays, discomfort from medical procedures, length of study, worry about experimentation, uncomfortable procedures, travel and travel costs, extra costs
|
Additional travel and extra costs
|
Duration of trial and follow- up
|
Patient preference for a particular treatment
|
Patient level factors
|
Patients’/parents’ preference for a particular treatment
|
Patients not wanting to change medication, not to take placebo, not to take experimental medication, not to take any medication, patient request for a specific intervention, strong patient preference for one treatment option
|
Patients’/parents’ attitudes towards taking experimental medicine or placebo
|
Aversion to treatment choice by random allocation
|
Treatment choice by random allocation
|
Worry about uncertainty
|
Patient level factors
|
Patients’/parents’ concerns about side effects of new drug
|
Efficacy of treatment on offer is unproven, distrust of hospital or medicine, fear of unknown
|
Concerns about information and consent
|
Information and consent related factors
|
Amount and complexity of trial information provided
|
Amount of information provided to research participants, wording of information, complexity of information provided, different forms of information presentation: written /verbal/video, limited reading skills and English not being the primary language, clinicians’ experience, difficulty in giving information, worry about level of information required and that information may be frightening, consent procedure barrier to recruitment
|
Patient level factors
|
Clarity in presentation of trial information
|
Clinical team factors
|
Experience and training of clinical team seeking consent
|
Social and emotional dynamics of trial discussion
|
Consent rate
|
Language or cultural barrier
|
Difficulty in approaching patents for consent
|
Clinician barriers
|
Time constraints
|
Clinical team factors
|
Clinical workload
|
Time pressures from usual clinical practice, time demands of recruitment and follow-up
|
Staffing and training
|
Clinical team factors
|
Research experience of clinical team
|
Lack of trained staff, no additional support, lack of research experience in clinicians, lack of available support staff
|
Availability of designated research team
|
Availability of research staff out of hours
|
Presence of designated research nurse/practitioner
|
Rewards and recognition
|
Excluded
|
Information available from the Chief Investigator
|
Economic incentives
|
Impact on doctor patient relationship fear of Adverse effect on doctor-patient relationship, perceived conflict in their role as clinicians and researchers
|
Clinical team factors
|
Clinician attitude to involving patients in research
|
Concern for patients
|
Concern about treatment toxicity, side effects, burden of trial for patients including travel distance and costs, reluctance to recruit severely ill patients
|
Problems in complying with the protocol
|
Clinical team factor
|
Clinician preference for a particular treatment
|
Trial level factor
|
Study protocol compared to clinical practice
|
Campbell et al. [[38]]
|
Hypothesis of factors tested for association with recruitment success
|
Trials with complex trial design do not recruit as well as simple trials
|
Trial level factor
|
Trial design
|
Less well-funded trials do not recruit well
|
Trial level factor
|
Funding
|
Trials without dedicated trial management expertise do not recruit as well as those with trial management expertise
|
Trial level factor
|
Trial management
|
Trial with multidisciplinary input recruit better than those that do not have this input
|
Excluded
|
Information available from the Chief Investigator
|
Trials with consumer involvement recruit better than those that do not
|
Excluded
|
Information available from the Chief Investigator
|
Trials that have a successful pilot phase recruit better than those that do not have a pilot phase
|
Trial level factor
|
Previous feasibility assessment
|
Previous pilot trial
|
Trials that have dedicated paid local coordinators recruit better than those that do not
|
|
Trial management
|
Cancer trials recruit better than non cancer trials
|
Trial level factor
|
Being a drug/cancer trial
|
Drug trials recruit better than non-drug trials
|
|
Being a drug/cancer trial
|
Trials funded through a response-mode funding have different recruitment rates to those funded through a commissioned process
|
Trial level factor
|
Funding
|
Reasons for delays in recruitment to the included cohort of trials
|
Problems with central staff, local research staff, internal problems (for example, staff)
|
Site level factor
|
Number of trained staff
|
Clinical team factor
|
Motivation of clinical team
|
Local clinical arrangements, merging/reorganization of trusts, major relocation of services, department policies
|
Site level factor
|
Local clinical arrangements
|
Funding issues
|
Trial level factor
|
Funding
|
Delays in ethical clearance
|
Excluded
|
Information available from the Chief Investigator
|
Research and Development (R&D) delays, time delay since grant application
|
Delays in supply of drug/placebo
|
Excluded
|
Information available from the Chief Investigator
|
Adverse publicity about medical research, external problem (for example, publicity)
|
Trial level factor
|
Publicity by the trial team
|
External publicity
|
Setting up general practitioner (GP) practices took longer than anticipated
|
Site level factor
|
Time to open up site
|
Simultaneous other local research projects, competing research, conflict with other trials
|
Site level factor
|
Competing local research projects
|
Delays due to changes in data legislation, changes in technology
|
Excluded
|
Information available from the Chief Investigator
|
Fewer eligible than expected, smaller percentage agreeing to participate, recruitment targets too ambitious
|
Trial level factor
|
Lack of pilot/feasibility assessment
|
Site level factor
|
Recruitment target
|
Absence of perceived clinical equipoise
|
Trial level factor
|
Clinical equipoise
|
Issues with procedures/interventions, trial process too demanding
|
Patient level factor
|
Additional trial investigations
|
Complexity of trial design, trial methodology considered too complex
|
Trial level factor
|
Trial design
|
Conflicting workload pressures, long waiting lists, additional theatre time required
|
Clinical team factor
|
Clinical workload
|
Language/written English difficulties
|
Patient level factor
|
Language or cultural barrier
|
Treatment preferences
|
Patient level factor
|
Patients’/parents’ preference for a particular treatment
|
Clinical team factor
|
Clinician preference for particular treatment
|
Research not considered as priority
|
Clinical team factor
|
Perceived importance of research generally in clinical practice
|
Perceived importance of the particular research question
|
No local access to intervention
|
Patient level factor
|
Intervention available only in the trial
|
Case studies of trials: common factors in the successes of part B trials
|
Facilitator
|
Classification
|
Factor derived
|
Important/interesting research question, topic important, urgent need for research, important question, timely and managed to roll several questions into one study
|
Clinical team factor
|
Perceived importance of the particular research question
|
Good design/good protocol, pragmatic study
|
Trial level factor
|
Trial design
|
Study protocol compared to clinical practice
|
Clinicians keen to recruit to trial
|
Clinical team factor
|
Motivation of clinical team
|
Clinician attitude to involving patients in research
|
Drugs already tested, so easy to explain to patients
|
Patient level factor
|
Familiarity with experimental treatment
|
Did not demand extra effort from patients, Impact on practice running and costs minimized, minimizing work for health professionals
|
Patient level factor
|
Additional trial demands
|
No competing trials for those centers/patients
|
Site level factor
|
Competing local research projects
|
Drugs not available outside the trial
|
Patient level factor
|
Intervention available only in the trial
|
Excellent trial management, trial units helpful, caring, annual meetings for all concerned, role of trial steering group
|
Trial level factor
|
Trial management
|
Good planning and organization by Clinical Trials Support Unit (CTSU), CTSU responsive, efficient, central organization of many aspects of research
|
Good communication between trial team and clinicians, flexibility of trial teams
|
Study team factor
|
Communication and coordination among study team members at site
|
Good public relations/feedback/updates
|
Trial level factor
|
Trial publicity
|
Good funding, National Health Service (NHS) funding
|
Trial level factor
|
Funding
|
Trial run by good team/infrastructure, Principal Investigator (PI) well respected, PIs worked hard to keep collaborators on board, trial team communicative, responsive and alert to problems. Communication within team, between team and collaborating clinicians
|
Study team factors
|
Motivation of the study team at site
|
Clinical team factor
|
Research experience of PI and study team members at site
|
Good trial team, good research assistants
|
Communication and coordination among study team members at site
|
Team worked hard at how to explain the study to patients
|
Communication and coordination between study team at site and Clinical Trials Unit (CTU)
|
Research experience of clinical team
|
Communication skills of clinical team
|
Role of research nurse
|
Clinical team factor
|
Presence of designated research nurse/practitioner
|
Study included everybody
|
Trial level factor
|
Patient inclusion criteria
|
Toerien et al. [[39]]
|
Study design, number of arms, control: active/placebo
|
Trial level factor
|
Trial design
|
Single/multicenter
|
Excluded
|
Information will be present
|
Intervention: drug/surgery/allied/others
|
Trial level factor
|
Being a drug/cancer/surgical/-----trial
|
Funding source
|
Trial level factor
|
Funding
|
Caldwell et al.[[40]]
|
|
|
Recruitment strategies
|
Novel trial designs
|
Trial level factor
|
Trial design
|
Recruiter differences
|
Information and consent related factors
|
Experience and training of doctors clinical team seeking consent
|
Senior doctors and nurses seeking consent
|
Financial incentives for patients/participants
|
Excluded
|
Monetary incentives not acceptable for clinical research in United Kingdom
|
Methods of providing information
|
Information and consent related factors
|
Amount and complexity of information provided
|
Patient level factor
|
Clarity in presentation of trial information
|
Consent rate
|
Treweek et al.[[2]]
|
|
|
Recruitment strategies
|
|
|
Design changes
|
Trial level factor
|
Trial design
|
Modification to the consent form or process
|
Patient level factor
|
Consent rate
|
Modification to the approach made to potential participants
|
Information and consent related factors
|
Amount and complexity of information provided
|
Clarity in presentation of trial information
|
Senior doctors and nurses seeking consent
|
Financial incentives for patients/participants
|
Excluded
|
Monetary incentives not acceptable for clinical research in United Kingdom
|
Modification to the training given to recruiters
|
Information and consent related factors
|
Experience and training of clinical team seeking consent
|
Greater contact between trial coordinator and trial sites |
Trial level factor |
Trial management |